J.P. Morgan’s Cory Kasimov moved bluebird bio to Neutral from Overweight in response to news it is suspending trials of a treatment for sickle cell disease.
J.P. Morgan’s Cory Kasimov moved bluebird bio to Neutral from Overweight in response to news it is suspending trials of a treatment for sickle cell disease.
Comments are closed.